Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity, Reactogenicity and Safety of Two Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) in Healthy Adults 18 to 40 Years of Age

NCT03652610 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT03652610
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03652610 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity, Reactogenicity and Safety of Two Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) in Healthy Adults 18 to 40 Years of Age
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
September 7, 2018
Completion date
June 11, 2019
Enrollment
996 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

infections, meningococcal